Last $0.73 USD
Change Today -0.004 / -0.54%
Volume 471.6K
RNN On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (RNN) Key Developments

Rexahn Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Rexahn Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Rexahn Pharmaceuticals, Inc. Names Richard Rodgers to the Board of Directors

Rexahn Pharmaceuticals, Inc. announced the appointment of Richard Rodgers to the company's Board of Directors. Mr. Rodgers was most recently Executive Vice President, Chief Financial Officer, Secretary and Treasurer of TESARO, which he co-founded, from March 2010 until August 2013. He previously served as the Chief Financial Officer from June 2009 to February 2010 of Abraxis BioScience. Prior to that, Mr. Rodgers served as Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, from 2004 until its acquisition by Eisai, in January 2008. Mr. Rodgers also serves as a director for Ardelyx, Inc.

Rexahn Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 09:00 AM

Rexahn Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 09:00 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Peter D. Suzdak, Chief Executive Officer and Director.

Rexahn Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2014

Rexahn Pharmaceuticals, Inc. reported earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported net loss of $1.9 million, or $0.01 per share, for the three months ended September 30, 2014, compared to a net loss of $2.1 million, or $0.02 per share, for the three months ended September 30, 2013. Included in net loss for the three months ended September 30, 2014 and 2013 is an unrealized gain (loss) on the fair value of warrants of $1.2 million and ($0.2 million), respectively. Loss from operations was $3.1 million and $1.8 million for the three months ended September 30, 2014 and 2013, respectively.

Rexahn Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 10:20 AM

Rexahn Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 10:20 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Peter D. Suzdak, Chief Executive Officer and Director, Tae Heum Jeong, Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNN:US $0.73 USD -0.004

RNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RNN.
View Industry Companies
 

Industry Analysis

RNN

Industry Average

Valuation RNN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.